BioRestorative Therapies, Inc. Common Stock (NV)
BRTXBioRestorative Therapies, Inc. (BRTX) is a biotechnology company focused on developing regenerative medicine solutions. It specializes in stem cell-based therapies aimed at treating various conditions, including pain management, sports medicine injuries, and degenerative diseases. The company's approach leverages its proprietary biologic products and advanced tissue engineering to promote healing and tissue regeneration.
Company News
BioRestorative Therapies has been granted a Type B meeting with the FDA to discuss an accelerated Biologics License Application approval pathway for BRTX-100, a stem cell-based treatment for chronic lumbar disc disease, with plans to request an expedited Phase 3 trial timeline.
BioRestorative Therapies presented promising preliminary data from its ongoing Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy for chronic lumbar disc disease. The data showed significant improvements in pain and function for a majority of subjects, with a favorable safety profile.
BioRestorative Therapies, Inc. announced that it has changed the time for its previously announced webcasted conference call to discuss its pipeline update. The company will now host the call at 10:30am EST on Thursday, February 27, 2025.
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform –
- Significant YoY improvement in operating performance -
